Cercano Management LLC Buys 9,108 Shares of DexCom, Inc. (NASDAQ:DXCM)

Cercano Management LLC increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 213,068 shares of the medical device company's stock after buying an additional 9,108 shares during the period. Cercano Management LLC owned about 0.06% of DexCom worth $26,440,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Sands Capital Management LLC boosted its position in DexCom by 4.3% during the 3rd quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company's stock worth $1,274,541,000 after buying an additional 557,543 shares during the period. Blair William & Co. IL boosted its position in DexCom by 1.7% during the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company's stock worth $420,517,000 after buying an additional 73,654 shares during the period. Northern Trust Corp boosted its position in DexCom by 2.4% during the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company's stock worth $363,545,000 after buying an additional 91,249 shares during the period. Charles Schwab Investment Management Inc. boosted its position in DexCom by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,160,961 shares of the medical device company's stock worth $201,618,000 after buying an additional 28,621 shares during the period. Finally, Winslow Capital Management LLC acquired a new stake in DexCom during the 3rd quarter worth approximately $173,120,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Raymond James lifted their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a "strong-buy" rating in a research report on Friday. Citigroup raised their price target on shares of DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. Canaccord Genuity Group raised their price target on shares of DexCom from $144.00 to $145.00 and gave the stock a "buy" rating in a report on Friday. UBS Group raised their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a "buy" rating in a report on Wednesday, April 10th. Finally, StockNews.com lowered shares of DexCom from a "buy" rating to a "hold" rating in a report on Tuesday, April 23rd. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $141.67.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares of the company's stock, valued at approximately $10,747,722.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the business's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company's stock, valued at approximately $5,839,974.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 20,321 shares of the business's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock valued at $25,530,859 in the last three months. 0.41% of the stock is currently owned by insiders.

DexCom Stock Down 9.9 %

DXCM stock traded down $13.67 during midday trading on Friday, reaching $124.34. 8,578,184 shares of the company's stock traded hands, compared to its average volume of 2,409,208. The company has a market cap of $49.24 billion, a price-to-earnings ratio of 80.22, a P/E/G ratio of 2.14 and a beta of 1.20. The firm's fifty day moving average price is $131.13 and its 200-day moving average price is $118.81. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.05. The business had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.38%. As a group, sell-side analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.